Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SGRY vs DBVT vs ALKS vs USPH vs SEM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SGRY
Surgery Partners, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$1.87B
5Y Perf.+6.8%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%
USPH
U.S. Physical Therapy, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$897M
5Y Perf.-20.4%
SEM
Select Medical Holdings Corporation

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$2.04B
5Y Perf.+89.2%

SGRY vs DBVT vs ALKS vs USPH vs SEM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SGRY logoSGRY
DBVT logoDBVT
ALKS logoALKS
USPH logoUSPH
SEM logoSEM
IndustryMedical - Care FacilitiesBiotechnologyBiotechnologyMedical - Care FacilitiesMedical - Care Facilities
Market Cap$1.87B$1712.35T$5.90B$897M$2.04B
Revenue (TTM)$3.34B$0.00$1.56B$695M$5.52B
Net Income (TTM)$-76M$-168M$153M$11M$134M
Gross Margin22.8%65.4%22.0%10.6%
Operating Margin11.8%12.3%12.2%5.8%
Forward P/E38.0x24.8x20.6x13.1x
Total Debt$4.02B$22M$70M$426M$3.70B
Cash & Equiv.$240M$194M$1.12B$36M$27M

SGRY vs DBVT vs ALKS vs USPH vs SEMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SGRY
DBVT
ALKS
USPH
SEM
StockMay 20May 26Return
Surgery Partners, I… (SGRY)100106.8+6.8%
DBV Technologies S.… (DBVT)10041.2-58.8%
Alkermes plc (ALKS)100216.4+116.4%
U.S. Physical Thera… (USPH)10079.6-20.4%
Select Medical Hold… (SEM)100189.2+89.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: SGRY vs DBVT vs ALKS vs USPH vs SEM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS and USPH are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. U.S. Physical Therapy, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. SEM and DBVT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
SGRY
Surgery Partners, Inc.
The Healthcare Pick

Among these 5 stocks, SGRY doesn't own a clear edge in any measured category.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the clearest fit if your priority is momentum.

  • +110.4% vs SGRY's -38.2%
Best for: momentum
ALKS
Alkermes plc
The Defensive Pick

ALKS has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • 9.8% margin vs SGRY's -2.3%
  • 5.4% ROA vs DBVT's -89.0%
Best for: sleep-well-at-night
USPH
U.S. Physical Therapy, Inc.
The Income Pick

USPH is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • Dividend streak 5 yrs, beta 0.93, yield 3.1%
  • Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
  • Beta 0.93, yield 3.1%, current ratio 1.01x
  • 16.3% revenue growth vs DBVT's -100.0%
Best for: income & stability and growth exposure
SEM
Select Medical Holdings Corporation
The Long-Run Compounder

SEM ranks third and is worth considering specifically for long-term compounding.

  • 158.5% 10Y total return vs USPH's 22.6%
  • Lower P/E (13.1x vs 20.6x)
  • Beta 0.46 vs DBVT's 1.26
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthUSPH logoUSPH16.3% revenue growth vs DBVT's -100.0%
ValueSEM logoSEMLower P/E (13.1x vs 20.6x)
Quality / MarginsALKS logoALKS9.8% margin vs SGRY's -2.3%
Stability / SafetySEM logoSEMBeta 0.46 vs DBVT's 1.26
DividendsUSPH logoUSPH3.1% yield, 5-year raise streak, vs SEM's 1.5%, (3 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+110.4% vs SGRY's -38.2%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

SGRY vs DBVT vs ALKS vs USPH vs SEM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SGRYSurgery Partners, Inc.
FY 2025
Healthcare Organization, Patient Service
49.4%$3.2B
Private Insurance
25.8%$1.7B
Government Revenue
21.1%$1.4B
Self-Pay Revenue
1.3%$88M
Other Services
1.3%$82M
Other Patient Service Revenue Sources
1.1%$71M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
USPHU.S. Physical Therapy, Inc.
FY 2025
Net Patient Revenues
83.3%$650M
Other Revenues Including Management Contract Revenues and Industrial Injury Prevention Services Revenues
16.7%$131M
SEMSelect Medical Holdings Corporation
FY 2025
Health Care, Patient Service, Non-Medicare
61.5%$3.4B
Health Care, Patient Service, Medicare
28.6%$1.6B
Service, Other
9.9%$538M

SGRY vs DBVT vs ALKS vs USPH vs SEM — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGSGRY

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

SEM and DBVT operate at a comparable scale, with $5.5B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to SGRY's -2.3%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSGRY logoSGRYSurgery Partners,…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcUSPH logoUSPHU.S. Physical The…SEM logoSEMSelect Medical Ho…
RevenueTrailing 12 months$3.3B$0$1.6B$695M$5.5B
EBITDAEarnings before interest/tax$572M-$112M$212M$107M$465M
Net IncomeAfter-tax profit-$76M-$168M$153M$11M$134M
Free Cash FlowCash after capex$208M-$151M$392M$67M$117M
Gross MarginGross profit ÷ Revenue+22.8%+65.4%+22.0%+10.6%
Operating MarginEBIT ÷ Revenue+11.8%+12.3%+12.2%+5.8%
Net MarginNet income ÷ Revenue-2.3%+9.8%+1.5%+2.4%
FCF MarginFCF ÷ Revenue+6.2%+25.1%+9.6%+2.1%
Rev. Growth (YoY)Latest quarter vs prior year+4.5%+28.2%+7.7%+5.0%
EPS Growth (YoY)Latest quarter vs prior year+6.7%+91.5%-4.1%-115.0%-18.2%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — SGRY and SEM each lead in 3 of 6 comparable metrics.

At 13.9x trailing earnings, SEM trades at a 66% valuation discount to USPH's 41.5x P/E. On an enterprise value basis, SGRY's 10.0x EV/EBITDA is more attractive than ALKS's 17.3x.

MetricSGRY logoSGRYSurgery Partners,…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcUSPH logoUSPHU.S. Physical The…SEM logoSEMSelect Medical Ho…
Market CapShares × price$1.9B$1712.35T$5.9B$897M$2.0B
Enterprise ValueMkt cap + debt − cash$5.7B$1712.35T$4.9B$1.3B$5.7B
Trailing P/EPrice ÷ TTM EPS-23.46x-0.76x24.76x41.55x13.93x
Forward P/EPrice ÷ next-FY EPS est.37.99x20.63x13.06x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple10.00x17.25x12.52x12.04x
Price / SalesMarket cap ÷ Revenue0.57x4.00x1.15x0.37x
Price / BookPrice ÷ Book value/share0.52x0.66x3.28x1.16x1.00x
Price / FCFMarket cap ÷ FCF9.57x12.28x14.71x5.33x
Evenly matched — SGRY and SEM each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to SEM's 1.82x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricSGRY logoSGRYSurgery Partners,…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcUSPH logoUSPHU.S. Physical The…SEM logoSEMSelect Medical Ho…
ROE (TTM)Return on equity-2.2%-130.2%+8.8%+1.4%+6.6%
ROA (TTM)Return on assets-0.9%-89.0%+5.4%+0.9%+2.3%
ROICReturn on invested capital+4.1%+18.9%+5.6%+4.8%
ROCEReturn on capital employed+5.2%-145.7%+14.2%+7.6%+7.0%
Piotroski ScoreFundamental quality 0–954755
Debt / EquityFinancial leverage1.14x0.13x0.04x0.55x1.82x
Net DebtTotal debt minus cash$3.8B-$172M-$1.0B$390M$3.7B
Cash & Equiv.Liquid assets$240M$194M$1.1B$36M$27M
Total DebtShort + long-term debt$4.0B$22M$70M$426M$3.7B
Interest CoverageEBIT ÷ Interest expense1.35x-189.82x32.30x15.42x4.41x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $2,773 for SGRY. Over the past 12 months, DBVT leads with a +110.4% total return vs SGRY's -38.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs SGRY's -25.8% — a key indicator of consistent wealth creation.

MetricSGRY logoSGRYSurgery Partners,…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcUSPH logoUSPHU.S. Physical The…SEM logoSEMSelect Medical Ho…
YTD ReturnYear-to-date-6.2%+4.9%+25.3%-24.6%+11.4%
1-Year ReturnPast 12 months-38.2%+110.4%+16.5%-14.3%+11.1%
3-Year ReturnCumulative with dividends-59.2%+19.7%+14.5%-43.7%+7.4%
5-Year ReturnCumulative with dividends-72.3%-69.1%+60.9%-43.4%-11.1%
10-Year ReturnCumulative with dividends-0.6%-87.0%-11.0%+22.6%+158.5%
CAGR (3Y)Annualised 3-year return-25.8%+6.2%+4.6%-17.4%+2.4%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

SEM leads this category, winning 2 of 2 comparable metrics.

SEM is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs SGRY's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSGRY logoSGRYSurgery Partners,…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcUSPH logoUSPHU.S. Physical The…SEM logoSEMSelect Medical Ho…
Beta (5Y)Sensitivity to S&P 5001.04x1.26x1.06x0.93x0.46x
52-Week HighHighest price in past year$24.18$26.18$36.60$93.50$16.99
52-Week LowLowest price in past year$11.41$7.53$25.17$58.55$11.65
% of 52W HighCurrent price vs 52-week peak+59.2%+76.3%+96.7%+63.1%+96.8%
RSI (14)Momentum oscillator 0–10063.348.160.246.160.9
Avg Volume (50D)Average daily shares traded1.5M252K2.3M171K2.1M
SEM leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

USPH leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: SGRY as "Buy", DBVT as "Buy", ALKS as "Buy", USPH as "Buy", SEM as "Hold". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 9.5% for SEM (target: $18). For income investors, USPH offers the higher dividend yield at 3.06% vs SEM's 1.55%.

MetricSGRY logoSGRYSurgery Partners,…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcUSPH logoUSPHU.S. Physical The…SEM logoSEMSelect Medical Ho…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHold
Price TargetConsensus 12-month target$18.60$46.33$44.00$102.00$18.00
# AnalystsCovering analysts2215281213
Dividend YieldAnnual dividend ÷ price+3.1%+1.5%
Dividend StreakConsecutive years of raises00050
Dividend / ShareAnnual DPS$1.80$0.25
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%+0.6%+4.9%
USPH leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 1 (Total Returns). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

SGRY vs DBVT vs ALKS vs USPH vs SEM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SGRY or DBVT or ALKS or USPH or SEM a better buy right now?

For growth investors, U.

S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Select Medical Holdings Corporation (SEM) offers the better valuation at 13. 9x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Surgery Partners, Inc. (SGRY) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SGRY or DBVT or ALKS or USPH or SEM?

On trailing P/E, Select Medical Holdings Corporation (SEM) is the cheapest at 13.

9x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, Select Medical Holdings Corporation is actually cheaper at 13. 1x.

03

Which is the better long-term investment — SGRY or DBVT or ALKS or USPH or SEM?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -72. 3% for Surgery Partners, Inc. (SGRY). Over 10 years, the gap is even starker: SEM returned +158. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SGRY or DBVT or ALKS or USPH or SEM?

By beta (market sensitivity over 5 years), Select Medical Holdings Corporation (SEM) is the lower-risk stock at 0.

46β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 173% more volatile than SEM relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 182% for Select Medical Holdings Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — SGRY or DBVT or ALKS or USPH or SEM?

By revenue growth (latest reported year), U.

S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Surgery Partners, Inc. grew EPS 54. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, USPH leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SGRY or DBVT or ALKS or USPH or SEM?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SGRY or DBVT or ALKS or USPH or SEM more undervalued right now?

On forward earnings alone, Select Medical Holdings Corporation (SEM) trades at 13.

1x forward P/E versus 38. 0x for Surgery Partners, Inc. — 24. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — SGRY or DBVT or ALKS or USPH or SEM?

In this comparison, USPH (3.

1% yield), SEM (1. 5% yield) pay a dividend. SGRY, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is SGRY or DBVT or ALKS or USPH or SEM better for a retirement portfolio?

For long-horizon retirement investors, Select Medical Holdings Corporation (SEM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

46), 1. 5% yield, +158. 5% 10Y return). Both have compounded well over 10 years (SEM: +158. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SGRY and DBVT and ALKS and USPH and SEM?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SGRY is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; USPH is a small-cap high-growth stock; SEM is a small-cap deep-value stock. USPH, SEM pay a dividend while SGRY, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SGRY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 13%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

USPH

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 13%
Run This Screen
Stocks Like

SEM

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.6%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.